Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NW-101C
- Development stage
- Phase 1
- Lead developer
- Neowise Biotechnology
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NW-101C is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by Neowise Biotechnology for the treatment of advanced solid malignant tumors. The therapy targets the Preferentially Expressed Antigen in Melanoma (PRAME), a cancer/testis antigen that is highly expressed in various solid tumors—including melanoma, lung cancer, and ovarian cancer—while maintaining restricted expression in healthy tissues. NW-101C utilizes T-cells genetically modified to express a high-affinity, natural TCR discovered via Neowise's proprietary CAST® (antigen-TCR pairing) platform. This TCR specifically recognizes a PRAME-derived peptide presented by the HLA-A*02:01 major histocompatibility complex (MHC). The drug is currently undergoing Phase 1 dose-escalation clinical trials to evaluate its safety, tolerability, and preliminary efficacy in patients with metastatic or heavily pretreated solid tumors that are HLA-A*02:01 positive and express the PRAME antigen.
- Other names
- PRAME-targeted TCR-T cells
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on NW-101C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NW-101C.